Search company, investor...

numares

numares-health.com

Founded Year

2004

Stage

Convertible Note | Alive

Total Raised

$11.72M

About numares

numares, formerly LipoFIT Analytic, is a specialized developer and provider of analytic and diagnostic test systems based on nuclear magnetic resonance (NMR) spectroscopy and numares' proprietary Magnetic Group Signaling (MGS) technology. numares HEALTH develops and markets in-vitro diagnostic tests with the CE-marking and integrated test systems for high-throughput use in clinical diagnostics and life science research. The highly standardized tests provide valuable information on the disease status of patients in the indication areas of cardiovascular disease, nephrology and oncology. In addition, numares HEALTH provides its test systems to the pharmaceutical industry on a fee-for-service basis. They can be used for example to investigate the therapeutic effects of medication as part of clinical trials. Furthermore, the company supports customers with complex issues and clinical trials, drawing on its many years of expertise and experience in the area of NMR spectroscopy and metabolomics.

Headquarters Location

Am BioPark 9

Regensburg, 93053,

Germany

+49 941 280 949-00

Missing: numares's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: numares's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing numares

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

numares is included in 8 Expert Collections, including Pharma Supply Chain.

P

Pharma Supply Chain

1,258 items

M

Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,540 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

numares Patents

numares has filed 1 patent.

The 3 most popular patent topics include:

  • Nuclear magnetic resonance
  • Spectroscopy
  • Magnetic resonance imaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/16/2018

1/25/2022

Nuclear magnetic resonance, Fluid dynamics, Mechanics, Geodesy, Spectroscopy

Grant

Application Date

11/16/2018

Grant Date

1/25/2022

Title

Related Topics

Nuclear magnetic resonance, Fluid dynamics, Mechanics, Geodesy, Spectroscopy

Status

Grant

Latest numares News

numares Appoints Dr. Gregory Heath As New Member of the Supervisory Board and Submits an Additional Test to the FDA

Dec 15, 2021

Download Dr. Gregory F. Heath, Member of the numares Supervisory Board (Photo: Business Wire) numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, is expected to allow evaluation of multi-marker algorithms for early detection of diseases. numares' tests* can be implemented on AXINON®: e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR), and determine risk for cardiovascular disease (CVD). numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration. (Photo: Business Wire) December 15, 2021 08:15 AM Eastern Standard Time BOSTON & REGENSBURG, Germany--( BUSINESS WIRE )--Leading NMR diagnostics company numares AG appoints Dr. Gregory Heath as new member of the Supervisory Board. Dr. Heath has a long career in the diagnostics and life sciences industry, including long-term experience in the development and launching of in vitro diagnostics (IVDs). He will assist numares in the commercialization of multi-marker-based diagnostic tests running on the company’s proprietary, AI-driven IVD platform, the AXINON® System, for which the company applied for two 510(k) clearances this year. “We are delighted to welcome Greg to the board,” said Dr. Volker Pfahlert, Chief Executive Officer of numares. “As we continue our focus on expansion in the United States, his depth of knowledge and substantial experience in the US diagnostics industry will help drive our diagnostic strategy and be invaluable to numares as it launches IVD products." With his appointment, Dr. Heath joins the numares Supervisory Board as the second, independent US expert after Ms. Kathy Bates of Mayo Clinic Laboratories, who has been supporting the Supervisory Board as first US advisor since her election in 2019. He brings with him more than 30 years of diagnostics experience. As a former General Manager of Diagnostics at Illumina Inc., Dr. Heath was responsible for building and managing the molecular Diagnostics Business Unit, as well as for the establishment of a CLIA lab and acquisition of service labs. Prior to this, he was SVP, Molecular Business at Roche Diagnostics, and held numerous roles in strategy, marketing, and business development during his career. He currently serves on the Scientific Advisory Board of Everlywell and is a strategic and scientific advisor to the diagnostics and life sciences industry. Winton Gibbons, President of numares GROUP in the US and co-CEO of numares AG adds "Greg is a great addition to our Supervisory Board. His extensive experience in the diagnostics industry will help numares to commercialize its pipeline of new tests in the US. These include AXINON® GFR(NMR), a novel multi-marker kidney function test, recently submitted for FDA clearance." Earlier this year, numares also announced its FDA 510(k) application for the AXINON® LDL-P test on the AXINON® System, an IVD platform based on Nuclear Magnetic Spectroscopy (NMR), combined with the company’s proprietary Magnetic Group Signaling (MGS®). MGS® enables simultaneous, highly standardized analysis of metabolites in human samples like blood and urine. The platform is used to develop and deploy novel diagnostic tests in clinical laboratories, applying the “numares model,” that identifies a set of metabolites, so-called "biomarker constellations,” via machine learning algorithms. This provides diagnostics solutions for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer. At the numares shareholders’ meeting in December 2021, Dr. Heath was elected as member of the supervisory board effective January 1st, 2022. You will find more information at https://www.numares.com/ and on our social media channels: LinkedIn , Facebook , YouTube and Twitter . Contacts numares

numares Frequently Asked Questions (FAQ)

  • When was numares founded?

    numares was founded in 2004.

  • Where is numares's headquarters?

    numares's headquarters is located at Am BioPark 9, Regensburg.

  • What is numares's latest funding round?

    numares's latest funding round is Convertible Note.

  • How much did numares raise?

    numares raised a total of $11.72M.

  • Who are the investors of numares?

    Investors of numares include Mayo Clinic, Eckenstein-Geigy-Stiftung, Mayfair Vermogensverwaltung, Bayern Kapital, KfW and 3 more.

  • Who are numares's competitors?

    Competitors of numares include Concert Pharmaceuticals, Banyan Biomarkers, Stemina Biomarker Discovery, Scynexis, Veracyte and 11 more.

Compare numares to Competitors

P
PhysioGenix

PhysioGenix offers pharmacogenetics and physiological genetics products and services

T
Total Pharmaceutical Care

Total Pharmaceutical Care, Inc. offers home healthcare and infusion therapy services

Chiral Technologies Logo
Chiral Technologies

Welcome to CHIRAL TECHNOLOGIES, INC., a supplier of columns, bulk stationary phases and separation services for chromatographic enantioselective separations to pharmaceutical, biotechnology, and fine chemicals companies. As users explore the company's site users will find many ways in which having CHIRAL TECHNOLOGIES as their partner can help users in all aspects of chromatographic resolution.

O
Oncology Research Therapeutics

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.

Banyan Biomarkers Logo
Banyan Biomarkers

Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.